L'intérêt à découvert pour ANI Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de ANI Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

ANI Pharmaceuticals (NASDAQ:ANIP) Stock, Rapport sur les intérêts à découvert

ANI PHARMACEUTICALS INC

ANI Pharmaceuticals

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">ANI Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>)</h3>
<ul class="wp-block-list">
<li>On May 22, ANI Pharma launched Phase 4 trial to test Cortrophin Gel dosing for gout flares at Massachusetts General Hospital. &#8220;Gout is a chronic disease that affects millions of patients, including acute flares that can cause extreme pain and temporary disability,&#8221; said Hyon Choi, MD, DrPH, principal investigator of the study and clinical investigator and physician in the Rheumatology Unit at Mass General Research Institute/Massachusetts General Hospital (MGH). &#8220;For some patients, conventional anti-inflammatory treatments do not provide adequate relief from these flares. We look forward to initiating this dose-ranging study, which we believe will provide valuable scientific information about Cortrophin Gel in the treatment of acute gout flares.&#8221; The company's stock fell around 18% over the past month and has a <a href="https://www.benzinga.com/quote/ANIP">52-week low of $52.50</a>.</li>
<li>RSI Value: 29.7</li>
<li>ANIP Price Action: Shares of ANI Pharmaceuticals gained 0.9% to close at $57.79 on Friday.</li>
<li>Edge Stock Ratings: 91.92 Momentum score with Value at 93.51. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="477" height="187" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044146/image-323.png" alt="" class="wp-image-927355" style="width:334px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044146/image-323.png 477w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044146/image-323-300x118.png 300w" sizes="(max-width: 477px) 100vw, 477px" /></figure>
<h3 class="wp-block-heading">Omeros Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>)</h3>
<ul class="wp-block-list">
<li>On May 15, Omeros posted a wider-than-expected quarterly loss. &#8220;We are pleased that our BLA for narsoplimab in TA-TMA has been accepted by FDA, which is a significant milestone for our narsoplimab program and for Omeros,&#8221; said Gregory A. Demopulos, M.D., Omeros&#8217; Chairman and Chief Executive Officer. The company's stock fell around 57% over the past month and <a href="https://www.benzinga.com/quote/OMER">has a 52-week low</a> of $2.97.</li>
<li>RSI Value: 25.3</li>
<li>OMER Price Action: Shares of Omeros fell 1.9% to close at $3.16 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0527">OMER stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0527"><img loading="lazy" decoding="async" width="915" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044237/image-324.png" alt="" class="wp-image-927356" style="width:621px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044237/image-324.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044237/image-324-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044237/image-324-768x711.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<h3 class="wp-block-heading">Agilon Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>)</h3>
<ul class="wp-block-list">
<li>On May 6, the company said total revenue of $1.53 billion fell 4% year-over-year in the first quarter. &#8220;I&#8217;m encouraged by our first quarter results and the progress we are making on key initiatives to drive improved operating performance. With our differentiated Total Care Model, our partnerships remain focused on the entire health of their patients, continuing to deliver significant quality outcomes, and cost-effective care to senior patients,&#8221; said Steven Sell, CEO, agilon health. The company's stock fell around 42% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/AGL">low of $1.50.</a></li>
<li>RSI Value: 29.9</li>
<li>AGL Ltd Price Action: Shares of Agilon Health rose 0.9% to close at $2.22 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0527">AGL shares</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0527"><img loading="lazy" decoding="async" width="883" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044331/image-325.png" alt="" class="wp-image-927358" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044331/image-325.png 883w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044331/image-325-300x289.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044331/image-325-768x741.png 768w" sizes="(max-width: 883px) 100vw, 883px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Dick&#8217;s Sporting Goods Stock Ahead Of Q1 Earnings</a></li>
</ul>
Photo via Shutterstock

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

ANIP

OMER

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>) today announced the initiation of a Phase 4 clinical trial at Massachusetts General Hospital to compare the safety and efficacy of two dose levels (40 USP
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) today announced the initiation of a Phase 4 clinical trial at Massachusetts General Hospital to compare the safety and efficacy of two dose levels (40 USP units and 80 USP units) of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) for the treatment of acute gout flares. Cortrophin Gel is indicated for short-term administration as an adjunctive therapy during an acute episode or exacerbation in acute gouty arthritis. Cortrophin Gel is contraindicated for intravenous administration. For additional important safety information, please see below.
"Gout is a chronic disease that affects millions of patients, including acute flares that can cause extreme pain and temporary disability," said Hyon Choi, MD, DrPH, principal investigator of the study and clinical investigator and physician in the Rheumatology Unit at Mass General Research Institute/Massachusetts General Hospital (MGH). "For some patients, conventional anti-inflammatory treatments do not provide adequate relief from these flares. We look forward to initiating this dose-ranging study, which we believe will provide valuable scientific information about Cortrophin Gel in the treatment of acute gout flares."
Dr. Choi has been a leading physician investigator with a primary focus on gout and other inflammatory arthritic conditions throughout his academic career. He has authored more than 150 gout-related peer-reviewed papers in leading journals, and his findings have been referenced by many articles as well as guidelines from the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Dr. Choi directs the MGH Gout &amp; Crystal Arthropathy Center and co-directs the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN), a non-profit organization dedicated to creating research and education initiatives to fill the knowledge gap in gout.
"This Phase 4 study in gout is the first clinical trial launched by ANI as part of our commitment to building the scientific evidence and clinical data supporting the use of Cortrophin Gel," said Mary Pao, MD, PhD, Chief Medical Officer of Rare Disease at ANI. "Our goal with the study is to generate meaningful clinical information for the dosing of Cortrophin Gel in patients with acute gout flares by comparing the safety and efficacy of two dose levels of the product. We believe this study will provide physicians with more data to inform their approach to patient care."
"We have seen steady growth in the use of Cortrophin Gel as an adjunctive therapy for gout flares since we launched our 1-mL vial, which we developed to help increase access for in-office treatment, in October 2023," said Nikhil Lalwani, President and Chief Executive Officer at ANI. "We believe our new Phase 4 study will provide valuable insights for patients and healthcare providers and further strengthen the profile of Cortrophin Gel in this indication."

Small Cap

ANI Pharma Launches Phase 4 Trial to Test Cortrophin Gel Dosing for Gout Flares at Massachusetts General Hospital

Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Buy and maintains $86 price target.

Price Target

Reiteration

Analyst Ratings

Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $86 Price Target

ANI Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) reported first-quarter adjusted earnings of $1.70 per share on Friday, up from $1.21 a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.38 per share</a>.
The company reported sales of $197.12 million, up 43.4% year over year, beating the&nbsp;<a href="https://www.benzinga.com/pressreleases/25/05/g45313408/ani-pharmaceuticals-reports-record-first-quarter-2025-financial-results-and-raises-2025-guidance" target="_blank" rel="noreferrer noopener">consensus of $180.68 million</a>. On an organic basis, excluding the <a href="https://www.benzinga.com/general/biotech/24/06/39460281/generics-player-ani-pharmaceuticals-strengthens-rare-disease-segment-with-380m-alimera-sciences-d" target="_blank" rel="noreferrer noopener">acquisition of Alimera</a>, total net revenues grew 31.7% year-over-year.
Net revenues for rare diseases, which include Cortrophin gel, Iluvien, and Yutiq, increased by 86.7% to $69.0 million. Cortrophin Gel net revenues increased 43.1% to $52.9 million, driven by increased volume.
Also Read: <a href="https://www.benzinga.com/25/05/45297381/viatris-shares-positive-data-from-investigational-contraceptive-patch-fast-acting-meloxicam-reduces-opioid-use-in-surgery-pain-trials" target="_blank" rel="noreferrer noopener">Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars</a>
During the quarter, the company saw increasing demand with the highest number of new patient starts and new cases initiated since launch. Cortrophin Gel experienced growth across existing and new prescribers, and ANI continued to expand the overall base of Cortrophin Gel prescribers. Iluvien and Yutiq generated net revenues of $16.1 million.&nbsp;
Performance for retina assets outside the U.S. was in line with expectations. Performance in the U.S. was impacted by reduced access for Medicare patients due to a lack of funding for third-party co-pay assistance programs, turnover in our sales force, and seasonality.&nbsp;
Brands&#8217; net revenues decreased 2.2% to $25.1 million, driven by a modest net decrease in volume.
Net revenues for Generic pharmaceutical products increased 40.5% to $98.7 million, driven by increased volumes in the base business and contributions from new product launches.
Reported gross margin decreased from 64.2% to 62.9%. Adjusted gross margin decreased from 64.4% to 63.1%, primarily due to mix, including significant growth of royalty-bearing products, including Cortrophin Gel.
Nikhil Lalwani, President and CEO, commented, &#8220;Based on our first quarter performance and favorable demand trends for Cortrophin Gel and our Generics and Brands portfolio, we are raising our 2025 guidance for total revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP EPS. While we await more visibility on potential pharmaceutical industry-specific tariffs, we believe we are well-positioned based on our strong U.S. footprint with over 90% of our revenues coming from finished goods manufactured in the U.S. and less than 5% of our revenues with direct reliance on China.&#8221;
Guidance: ANI Pharmaceuticals raised its 2025 revenue guidance <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/44046417/ani-pharmaceuticals-expects-strong-start-to-2025-on-back-of-cortrophin-gel-and-generics-lifts-annual-forecast" rel="noreferrer noopener">from $756 million to $776 million</a> to $768 million to $793 million, versus the consensus of $769.64 million.
The company expects adjusted EBITDA of $195 million to $205 million compared to prior guidance of $190 million to $200 million.
ANI Pharmaceuticals expects 2025 adjusted EPS of $6.27 to $6.62 versus prior guidance of $6.12 to $6.49 and a consensus of $6.34.
Price Action: ANIP stock is down 4.95% to $67.99 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45304831/in-a-recession-these-waste-management-stocks-have-outperformed-sp500-historically" target="_blank" rel="noreferrer noopener">In A Recession, These Waste Management Stocks Have Outperformed S&amp;P 500 Historically</a></li>
</ul>
Image by JHVEPhoto via Shutterstock

Earnings

Guidance

Health Care

Movers

General

Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact

ANI Pharmaceuticals Raises FY2025 Adj EPS Guidance from $6.12-$6.49 to $6.27-$6.62 vs $6.34 Est; Raises FY2025 Sales Guidance from $756.00M-$776.00M to $768.00M-$793.00M vs $769.64M Est

ANI Pharmaceuticals Q1 2025 Adj. EPS $1.70 Beats $1.38 Estimate, Sales $197.12M Beat $180.68M Estimate

<h3>Companies Reporting Before The Bell</h3>
• NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $120.47 million. 
• Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $28.07 million. 
• Gogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGO#NASDAQ">GOGO</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $214.44 million. 
• Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) is estimated to report quarterly earnings at $0.08 per share on revenue of $21.60 million. 
• ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) is projected to report quarterly loss at $0.06 per share on revenue of $180.69 million. 
• TELUS Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIXT#NYSE">TIXT</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $650.27 million. 
• EchoStar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) is projected to report quarterly loss at $0.80 per share on revenue of $3.87 billion. 
• Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) is projected to report quarterly loss at $0.05 per share on revenue of $285.18 million. 
• Essent Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESNT#NYSE">ESNT</a>) is projected to report quarterly earnings at $1.65 per share on revenue of $310.79 million. 
• Veren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRN#NYSE">VRN</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $719.90 million. 
• TXNM Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXNM#NYSE">TXNM</a>) is expected to report quarterly earnings at $0.20 per share on revenue of $432.72 million. 
• Algonquin Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $652.63 million. 
• Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) is expected to report quarterly earnings at $0.59 per share on revenue of $261.77 million. 
• Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $57.10 million. 
• American Strategic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYC#NYSE">NYC</a>) is projected to report earnings for its first quarter. 
• Plains All American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $14.00 billion. 
• Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) is expected to report quarterly earnings at $0.95 per share on revenue of $10.31 billion. 
• Creative Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>) is estimated to report earnings for its first quarter. 
• uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) is estimated to report quarterly loss at $0.96 per share on revenue of $6.10 million. 
• Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) is projected to report earnings for its first quarter. 
• Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) is likely to report quarterly loss at $0.01 per share on revenue of $23.68 million. 
• Ultralife (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULBI#NASDAQ">ULBI</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $54.50 million. 
• TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) is projected to report quarterly loss at $0.06 per share on revenue of $47.69 million. 
• NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) is likely to report quarterly loss at $0.14 per share on revenue of $1.87 million. 
• PAR Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAR#NYSE">PAR</a>) is expected to report quarterly loss at $0.04 per share on revenue of $105.16 million. 
• InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $1.45 million. 
• Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) is projected to report quarterly loss at $0.05 per share on revenue of $29.22 million. 
• Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) is projected to report quarterly loss at $0.52 per share on revenue of $918.50 million. 
• Koppers Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOP#NYSE">KOP</a>) is projected to report quarterly earnings at $0.56 per share on revenue of $488.00 million. 
• Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) is likely to report quarterly loss at $0.27 per share on revenue of $6.63 million. 
• Associated Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AC#NYSE">AC</a>) is estimated to report quarterly loss at $0.47 per share on revenue of $5.33 billion. 
• Federal Agricultural (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGM#NYSE">AGM</a>) is estimated to report earnings for its first quarter. 
• Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) is estimated to report quarterly loss at $0.90 per share on revenue of $10.73 million. 
• First Trust Switzerland AlphaDEX Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSZ#NASDAQ">FSZ</a>) is projected to report quarterly earnings at $0.25 per share on revenue of $171.64 million. 
• Sylvamo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLVM#NYSE">SLVM</a>) is likely to report quarterly earnings at $0.69 per share on revenue of $817.58 million. 
• Strawberry Fields REIT (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STRW#AMEX">STRW</a>) is projected to report earnings for its first quarter. 
• AMC Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>) is estimated to report quarterly earnings at $0.81 per share on revenue of $567.23 million. 
• Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) is likely to report quarterly loss at $0.17 per share on revenue of $586.15 million. 
• Construction Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROAD#NASDAQ">ROAD</a>) is likely to report quarterly loss at $0.06 per share on revenue of $559.61 million. 
• Starwood Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>) is projected to report quarterly earnings at $0.49 per share on revenue of $468.00 million. 
• BKV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKV#NYSE">BKV</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $208.66 million. 
• 1stdibs.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIBS#NASDAQ">DIBS</a>) is expected to report quarterly loss at $0.13 per share on revenue of $22.28 million. 
• Plains GP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAGP#NASDAQ">PAGP</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $12.97 billion. 
<h3>Companies Reporting After The Bell</h3>
• Motorsport Games (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) is estimated to report earnings for its first quarter. 
• ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) is projected to report earnings for its first quarter. 
• Hawaiian Electric Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) is expected to report earnings for its first quarter. 
• Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) is projected to report earnings for its first quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMCX

ANIK

CLMT

CMCT

DCBO

DIBS

EMBC

ESNT

GOGO

INUV

KYMR

LOGC

MSGM

NSPR

OCGN

ORLA

PAGP

QURE

ROAD

RPID

SATS

SLVM

STRW

STWD

TIXT

TXNM

ULBI

WULF

Earnings Scheduled For May 9, 2025

ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) is gearing up to announce its quarterly earnings on Friday, 2025-05-09. Here's a quick overview of what investors should know before the release.
Analysts are estimating that ANI Pharmaceuticals will report an earnings per share (EPS) of $-0.10.
Investors in ANI Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $1.34, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at ANI Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.29</td>
<td>1.09</td>
<td>0.94</td>
<td>0.99</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.63</td>
<td>1.34</td>
<td>1.02</td>
<td>1.21</td>
</tr>
<tr>
<td>Price Change %</td>
<td>13.0%</td>
<td>5.0%</td>
<td>-10.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746716484_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of ANI Pharmaceuticals were trading at $70.82 as of May 07. Over the last 52-week period, shares are up 2.98%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Take on ANI Pharmaceuticals</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on ANI Pharmaceuticals.
The consensus rating for ANI Pharmaceuticals is Buy, derived from 7 analyst ratings. An average one-year price target of $84.29 implies a potential 19.02% upside.
<h3>Peer Ratings Overview</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of and ANI Pharmaceuticals, three key industry players, offering insights into their relative performance expectations and market positioning.
<h3>Insights: Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for and ANI Pharmaceuticals, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANI Pharmaceuticals</td>
<td>Buy</td>
<td>44.75%</td>
<td>$110.29M</td>
<td>-2.64%</td>
</tr>
</tbody>
</table>

Key Takeaway:
ANI Pharmaceuticals ranks at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. However, it ranks at the top for Consensus rating. For Return on Equity, it is in the middle compared to its peers.
<h3>Get to Know ANI Pharmaceuticals Better</h3>
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
<h3>ANI Pharmaceuticals's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: ANI Pharmaceuticals displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 44.75%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -5.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -2.64%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): ANI Pharmaceuticals's ROA excels beyond industry benchmarks, reaching -0.83%. This signifies efficient management of assets and strong financial health.
Debt Management: ANI Pharmaceuticals's debt-to-equity ratio is below the industry average at 1.55, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/ANIP/earnings">To track all earnings releases for ANI Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of ANI Pharmaceuticals's Earnings

Demonstrated Dose Dependent Effect in EAU
Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting
PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) today announced preclinical data on the use of Purified Cortrophin&#xAE; Gel (repository corticotropin injection USP) (Cortrophin Gel) in an EAU mouse model.
"In a preclinical model of autoimmune uveitis, Cortrophin Gel reduced levels of inflammatory molecules without stimulating an adverse immune response," said Mary Pao, MD, PhD, Chief Medical Officer of Rare Disease at ANI. "The results further support our understanding of Cortrophin Gel's mechanism of action."
An experimental autoimmune uveitis (EAU) mouse model was used to determine the impact of four doses (4, 40, 160 or 400 U/kg) of repository corticotrophin injection (RCI, an equivalent to Cortrophin Gel in this model). The results showed a significant dose-dependent effect on the suppression of EAU at all doses, with the greatest suppression of EAU at the 400 U/kg dose. RCI also significantly suppressed the production of cytokines implicated in inflammation and immune system activation. Additionally, 400 U/kg Purified Cortrophin Gel treatment suppressed retinal damage caused by EAU, similar to α-MSH treatment, compared to placebo.
"The data presentation at ARVO is part of ANI's broader commitment to clinical research for our products and, specific to Cortrophin Gel, we are committed to building on the scientific evidence and clinical data supporting its mechanism of action and clinical use," said Nikhil Lalwani, President and Chief Executive Officer at ANI.

Biotech

ANI Pharmaceuticals Announces Presentation Of Preclinical Data On Use Of Purified Cortrophin Gel In An Experimental Autoimmune Uveitis Mouse Model

Truist Securities analyst Gregory Fraser maintains ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Hold and raises the price target from $62 to $65.

Truist Securities Maintains Hold on ANI Pharmaceuticals, Raises Price Target to $65

During the last three months, 6 analysts shared their evaluations of ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $87.5, a high estimate of $94.00, and a low estimate of $80.00. This current average has decreased by 2.23% from the previous average price target of $89.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1744408856_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of ANI Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Vamil Divan &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $86.00&#x7C;$86.00 &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $94.00&#x7C;$94.00 &#x7C; 
&#x7C;Glen Santangelo &#x7C;Jefferies &#x7C;Announces &#x7C;Buy &#x7C; $80.00&#x7C;- &#x7C; 
&#x7C;Ekaterina Knyazkova &#x7C;JP Morgan &#x7C;Announces &#x7C;Overweight &#x7C; $85.00&#x7C;- &#x7C; 
&#x7C;Vamil Divan &#x7C;Guggenheim &#x7C;Raises &#x7C;Buy &#x7C; $86.00&#x7C;$84.00 &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $94.00&#x7C;$94.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ANI Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ANI Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for ANI Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ANI Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANIP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ANI Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering ANI Pharmaceuticals: A Closer Look</h2>
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
<h3>ANI Pharmaceuticals's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: ANI Pharmaceuticals's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 44.75%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: ANI Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -5.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -2.64%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.83%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.55, ANI Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)

ANI Pharmaceuticals Announced The Launch Of Nitazoxanide Tablets, 500 Mg

Nikhil Lalwani, President and CEO of ANI stated, "This transaction reflects our commitment to strengthening our Retina portfolio and maximizing the long-term value of ILUVIEN and YUTIQ. By eliminating this royalty obligation, we have enhanced our financial flexibility and ability to accelerate growth as we pursue our purpose of ‘Serving Patients, Improving Lives.'"

ANI Pharmaceuticals Completed The Buyout Of Its 3.125% Perpetual Royalty Obligation To SWK Funding On Worldwide Net Revenues Of Iluvien And Yutiq For A One-time Payment Of $17.25M

HC Wainwright &amp; Co. analyst Oren Livnat reiterates ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Buy and maintains $94 price target.

HC Wainwright & Co. Reiterates Buy on ANI Pharmaceuticals, Maintains $94 Price Target

4 analysts have expressed a variety of opinions on ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for ANI Pharmaceuticals, presenting an average target of $86.25, a high estimate of $94.00, and a low estimate of $80.00. This current average represents a 3.09% decrease from the previous average price target of $89.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741960857_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of ANI Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Ekaterina Knyazkova</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ANI Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of ANI Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of ANI Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ANI Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANIP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ANI Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into ANI Pharmaceuticals's Background</h2>
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
<h3>A Deep Dive into ANI Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: ANI Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 44.75%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ANI Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -5.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): ANI Pharmaceuticals's ROE excels beyond industry benchmarks, reaching -2.64%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ANI Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.83%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 1.55, ANI Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts

Jefferies analyst Glen Santangelo initiates coverage on ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Buy rating and announces Price Target of $80.

Initiation

Jefferies Initiates Coverage On ANI Pharmaceuticals with Buy Rating, Announces Price Target of $80

The expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).&nbsp;
The approval also includes other updates to the label including to the Warnings and Precautions section.&nbsp;
As previously announced, the Company plans to market ILUVIEN for chronic NIU-PS in addition to its current indication of diabetic macular edema (DME) in the U.S. ILUVIEN is already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries.

ANI Pharmaceuticals Says FDA Approved Expanded Label For ILUVIEN

JP Morgan analyst Ekaterina Knyazkova initiates coverage on ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Overweight rating and announces Price Target of $85.

JP Morgan Initiates Coverage On ANI Pharmaceuticals with Overweight Rating, Announces Price Target of $85

Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Buy and raises the price target from $84 to $86.

Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $86

Press Releases

ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets

ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET

ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model

ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th

Comments

ANI Pharmaceuticals

Intérêt court

ANI Pharmaceuticals (NASDAQ:ANIP) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL